‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal

A recent survey shows heavy opposition to the proposal which could leave university licensing struggling, chill investment in startups, and threaten technology transfers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Trump’s march-in rights threat: Why pharma is rethinking university deals

9 September 2025 Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen.

Americas

Harvard’s patent portfolio at risk as Trump turns up the pressure

11 August 2025 Administration targets university’s federally funded research | Commerce Secretary warns of patent seizure under Bayh-Dole Act | Harvard given deadline to provide list of federally funded patents | Uncertainty continues across universities amid broader research cuts.

article

Pharma body attacks ‘vague’ march-in rights plan

8 February 2024 PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.

More features

Stress, anxiety, burnout: ‘Real change needed’ in law

Gilead blocks HIV drug generics for more than 10 years

Bridging Brunel and AI: Why CIPA sees ‘a golden opportunity’

Teva in-house counsel jumps to private practice

Brazil’s patent shake-up: How pharma is handling a new reality

Eli Lilly strikes AI drug discovery deal with US biotech

Why AI drug discovery has an IP problem and what can be done

Blank Rome adds more patent attorneys in ‘strategic expansion’

‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal

More on this story

Editor's picks

Editor's picks

More features